Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025On track to initiate U.S.

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic ...

MNKD-201, an inhaled formulation of nintedanib for IPF, was shown to be safe and well tolerated in a clinical trial with ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase 1b trial of safety and tolerability of inhaled LTI-03 for idiopathic pulmonary fibrosis (IPF).

Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...

The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...

The deal follows a three-year stand off between NICE, NHS England and Vertex over the price of cystic fibrosis drugs including Orkambi, leading to campaigns from patient groups to make the drugs ...